Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Angeles Clinic and Research Institute has initiated a global, pivotal Phase III clinical trial with Elesclomol, an oxidative stress inducer, for treating advanced melanoma.
Subscribe to our email newsletter
According to the institute, Elesclomol has a completely new and distinct mechanism of action from other cancer therapies as it induces a potent stress response in cancer cells, driving programmed cell death and enhancing the activity of chemotherapy. Elesclomol is being developed by Synta Pharmaceuticals, which is sponsoring the trial.
Steven O’Day, director of the melanoma program at the Angeles Clinic and Research Institute and principal investigator of the study, said: “To date, the clinical data we have seen for Elesclomol have shown a positive benefit to patients suffering from metastatic melanoma and provide a strong scientific basis for initiating this Phase III study.”